{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:12:04Z","timestamp":1793747524576,"version":"4.6.1"},"reference-count":48,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2019,11,21]]},"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:p>Age-related macular degeneration is the leading cause of vision loss in the developed world, with the expected number of affected elderly individuals reaching 17.8\u2009million. Antivascular endothelial growth factor (anti-VEGF) injection therapy has been instrumental in treating a disease process that was previously thought to be untreatable. Over the past two decades, landmark studies have demonstrated the efficacy of different anti-VEGF medications and investigated the optimal dosing regimen and delivery mechanism to increase overall vision and minimise patient burden. In this review, we outline landmark neovascular age-related macular degeneration clinical trials that have demonstrated level 1 evidence for its usage or have contributed to the understanding of how to dose these agents.<\/jats:p>","DOI":"10.1136\/bmjophth-2019-000398","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T05:26:36Z","timestamp":1576473996000},"page":"e000398","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":114,"title":["Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review"],"prefix":"10.1136","volume":"4","clinical-trial-number":[{"clinical-trial-number":"nct02462928","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02462486","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02307682","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02434328","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02510794","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04049266","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03953079","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03823287","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03479372","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03066258","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03748784","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Saira","family":"Khanna","sequence":"first","affiliation":[{"name":"Ophthalmology and Visual Sciences, University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Komati","sequence":"additional","affiliation":[{"name":"Ophthalmology and Visual Sciences, University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Eichenbaum","sequence":"additional","affiliation":[{"name":"Retina Vitreous Associates of Florida, St. Petersburg, Florida, USA"},{"name":"USF Health Morsani College of Medicine, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishani","family":"Hariprasad","sequence":"additional","affiliation":[{"name":"University of Chicago Laboratory Schools, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Ciulla","sequence":"additional","affiliation":[{"name":"Midwest Eye Institute, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0985-9551","authenticated-orcid":false,"given":"Seenu M","family":"Hariprasad","sequence":"additional","affiliation":[{"name":"Ophthalmology and Visual Sciences, University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,12,15]]},"reference":[{"key":"2025090109314714000_4.1.e000398.1","doi-asserted-by":"crossref","DOI":"10.1001\/archophthalmol.2010.318","article-title":"Prevalence of age-related macular degeneration in the US population","volume":"129","author":"Klein","year":"2011","journal-title":"Arch Ophthal"},{"key":"2025090109314714000_4.1.e000398.2","doi-asserted-by":"crossref","unstructured":"Klein BEK . Forecasting age-related macular degeneration through 2050. JAMA 2009;301.doi:10.1001\/jama.2009.729","DOI":"10.1001\/jama.2009.729"},{"key":"2025090109314714000_4.1.e000398.3","doi-asserted-by":"crossref","DOI":"10.1001\/archopht.1980.01020030826002","article-title":"Macular photocoagulation study","volume":"98","author":"Fine","year":"1980","journal-title":"Arch Ophthalmol"},{"key":"2025090109314714000_4.1.e000398.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.07.038"},{"key":"2025090109314714000_4.1.e000398.5","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2005-6-2-209","article-title":"The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease","volume":"6","author":"Holmes","year":"2005","journal-title":"Genome Biol"},{"key":"2025090109314714000_4.1.e000398.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042760"},{"key":"2025090109314714000_4.1.e000398.7","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305327"},{"key":"2025090109314714000_4.1.e000398.8","unstructured":"Ciulla TA , Hussain RM , Pollack JS , et al . Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular AMD Patients: A \u201cReal World\u201d Analysis in 49,485 Eyes. Ophthalmology Retina . [Epub ahead of print: May 2019]."},{"key":"2025090109314714000_4.1.e000398.9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","article-title":"Real-World outcomes of Anti\u2013Vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmology Retina"},{"key":"2025090109314714000_4.1.e000398.10","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-World vision in age-related macular degeneration patients treated with single Anti\u2013VEGF drug type for 1 year in the iris registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"2025090109314714000_4.1.e000398.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.12.018"},{"key":"2025090109314714000_4.1.e000398.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.04.030"},{"key":"2025090109314714000_4.1.e000398.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"2025090109314714000_4.1.e000398.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.08.012"},{"key":"2025090109314714000_4.1.e000398.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.10.018"},{"key":"2025090109314714000_4.1.e000398.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"2025090109314714000_4.1.e000398.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.01.028"},{"key":"2025090109314714000_4.1.e000398.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.01.024"},{"key":"2025090109314714000_4.1.e000398.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.12.019"},{"key":"2025090109314714000_4.1.e000398.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.10.014"},{"key":"2025090109314714000_4.1.e000398.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.009"},{"key":"2025090109314714000_4.1.e000398.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"2025090109314714000_4.1.e000398.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"2025090109314714000_4.1.e000398.24","doi-asserted-by":"publisher","DOI":"10.3310\/hta19880"},{"key":"2025090109314714000_4.1.e000398.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.10.004"},{"key":"2025090109314714000_4.1.e000398.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.09.004"},{"key":"2025090109314714000_4.1.e000398.27","unstructured":"Efficacy and safety of RTH258 versus aflibercept. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02307682 [Accessed 14 Apr 2019]."},{"key":"2025090109314714000_4.1.e000398.28","unstructured":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 2. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02434328"},{"key":"2025090109314714000_4.1.e000398.29","doi-asserted-by":"crossref","unstructured":"Dugel PU , Koh A , Ogura Y , et al . Hawk and harrier: phase 3, multicenter, randomized, double-masked trials of Brolucizumab for neovascular age-related macular degeneration. Ophthalmology 2019. doi:doi:10.1016\/j.ophtha.2019.04.017 . [Epub ahead of print: Apr 2019].","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"2025090109314714000_4.1.e000398.30","unstructured":"Khurana R . Safety and efficacy of abicipar in patients with neovascular age-related macular degeneration 2018."},{"key":"2025090109314714000_4.1.e000398.31","unstructured":"Molecular Partners . Allergan and molecular partners announce Topline safety results from maple study of Abicipar pegol 2019;2019."},{"key":"2025090109314714000_4.1.e000398.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.041"},{"key":"2025090109314714000_4.1.e000398.33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","article-title":"Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis compared to Avastin study Treat-and-Extend protocol","volume":"123","author":"Berg","year":"2016","journal-title":"Ophthalmology"},{"key":"2025090109314714000_4.1.e000398.34","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","article-title":"Prospective trial of Treat-and-Extend versus monthly dosing for neovascular age-related macular degeneration","volume":"122","author":"Wykoff","year":"2015","journal-title":"Ophthalmology"},{"key":"2025090109314714000_4.1.e000398.35","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","article-title":"Randomized trial of Treat-and-Extend versus monthly dosing for neovascular age-related macular degeneration","volume":"1","author":"Wykoff","year":"2017","journal-title":"Ophthalmology Retina"},{"key":"2025090109314714000_4.1.e000398.36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-Extend versus monthly regimen in neovascular age-related macular degeneration","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"key":"2025090109314714000_4.1.e000398.37","unstructured":"Eichenbaum D , Bann-Mo D , Bhakta A , et al . \u201cIt\u2019s the Patient Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients with Wet nAMD.\u201d Poster on Demand. Chicago: American Society of Retina Specialists, 2019."},{"key":"2025090109314714000_4.1.e000398.38","unstructured":"Stone TW , Hahn P , Raef S , eds. ASRS 2019 Preferences and Trends Membership Survey, 2019."},{"key":"2025090109314714000_4.1.e000398.39","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3928\/23258160-20170928-01","article-title":"Treatment Burden in Neovascular AMD:Visual Acuity Outcomes are Associated With Anti-VEGF Injection Frequency","volume":"48","author":"Hussain","year":"2017","journal-title":"Ophthalmic Surgery, Lasers and Imaging Retina"},{"key":"2025090109314714000_4.1.e000398.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.03.046"},{"key":"2025090109314714000_4.1.e000398.41","unstructured":"Study of the efficacy and safety of the ranibizumab Port delivery system (RPDS) for sustained delivery of ranibizumab in participants with subfoveal neovascular age-related macular degeneration (AMD) (ladder). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02510794 [Accessed 14 Apr 2019]."},{"key":"2025090109314714000_4.1.e000398.42","unstructured":"A study to evaluate the efficacy and safety of KSI-301, an anti-VEGF antibody biopolymer conjugate, versus aflibercept in patients with neovascular (wet) age-related macular degeneration. (dazzle). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04049266 [Accessed 9 Sep 2019]."},{"key":"2025090109314714000_4.1.e000398.43","unstructured":"A depot formulation of sunitinib malate (GB-102) compared to aflibercept in subjects with wet AMD (ALTISSIMO). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03953079 [Accessed 9 Sep 2019]."},{"key":"2025090109314714000_4.1.e000398.44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","article-title":"Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 Phoenix study","volume":"197","author":"Liu","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"2025090109314714000_4.1.e000398.45","unstructured":"A study to evaluate the efficacy and safety of Faricimab in participants with neovascular age-related macular degeneration (TENAYA). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03823287 [Accessed 9 Sep 2019]."},{"key":"2025090109314714000_4.1.e000398.46","unstructured":"Study of PAN-90806 eye drops, suspension for neovascular AMD, 2019. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03479372"},{"key":"2025090109314714000_4.1.e000398.47","unstructured":"RGX-314 gene therapy for neovascular AMD trial, 2019. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03066258"},{"key":"2025090109314714000_4.1.e000398.48","unstructured":"ADVM-022 gene therapy for wet AMD (optic). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03748784 [Accessed 9 Sep 2019]."}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2019-000398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:31:54Z","timestamp":1756744314000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2019-000398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12,15]]},"published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1136\/bmjophth-2019-000398"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2019-000398","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}